Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
Sponsor: Keymed Biosciences Co.Ltd
Summary
This is a randomized, open-label, phase IB/II clinical study to evaluate the safety and preliminary efficacy of CM313(SC) injection in patients with Platelet Transfusion Refractoriness.
Official title: A Phase IB/II Clinical Study to Assess the Safety and Preliminary Efficacy of CM313(SC) Injection in Subjects With Platelet Transfusion Refractoriness
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
110
Start Date
2025-03-25
Completion Date
2027-11-16
Last Updated
2025-08-15
Healthy Volunteers
No
Conditions
Interventions
CM313(SC) injection-low dose
Phase IB:CM313(SC) administered at low dose according to the protocol. Phase II:CM313(SC) administered at different doses based on Phase IB's results.
CM313(SC) injection-high dose
Phase IB:CM313(SC) administered at high dose according to the protocol. Phase II:CM313(SC) administered at different doses based on Phase IB's results.
Locations (1)
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China